Pfizer expands access to the Covid pill. Following the path already taken by Merck, the pharmaceutical giant signs a licensing agreement with the UN-backed Medicines Patent Pool to expand access to its antiviral pill in developing countries. Agreement to increase supplies of Pfizer’s anti-viral pills. In fact, generic drug manufacturers will be able to produce the drug in advance of the authorities’ green light to speed up supplies to low- and middle-income countries. The agreement is the first with which the company opens to the sharing of technology on an anti Covid product.
Pfizer announces the anti Covid pill: “Reduces deaths and hospitalizations by 89%, soon the request for ok to the Fda”
by Fiammetta Cupellaro
Under the terms of the licensing agreement between Pfizer and MPP, qualified generic drug manufacturers worldwide that are sublicensed will be able to supply Pf-07321332 in combination with Ritonavir to 95 countries, covering up to approximately 53 per cent of the world‘s population, including all low- and lower-middle-income countries and some upper-middle-income countries in sub-Saharan Africa, as well as countries that have moved from low- and middle-income status to the medium-high one in the last five years.
Covid Watch
Anti Covid pills work but they cannot replace vaccines: here’s why
by Aureliano Stingi
Covid-19 remains classified as a public health emergency of international concern by the World Health Organization and Pfizer will not receive royalties on sales in low-income countries and will waive additional royalties on sales in all countries covered by the agreement.
Anti Covid pill, this is how the first antivirals against the virus work
by Daniele Banfi
.